Analysis of incidence and mortality of male urogenital system tumors in China from 1990 to 2019

doi:10.3760/cma.j.cn371439-20240509-00106

Abstract

Abstract:

Objective To examine the prevalence and trends of male urogenital system tumors in China from 1990 to 2019. Methods The Global Burden of Disease Study 2019 database was used to analyze the incidence and mortality of male urogenital tumors among different age groups and years in China. Joinpoint 5.2.0 software was utilized to analyze the incidence and mortality trends of male urogenital tumors in China from 1990 to 2019. Standardized incidence and mortality rates of male urogenital system tumors in China， in the world and in different sociodemographic index （SDI） regions were compared. Results In 2019， the rank of incidence of male urogenital system tumors in China from high to low was prostate cancer （21.17/100 000）， bladder cancer （11.41/100 000）， kidney cancer （5.87/100 000） and testicular cancer （2.37/100 000）. The rank of mortality was consistent with the rank of incidence， which was prostate cancer （7.50/100 000）， bladder cancer （4.35/100 000）， kidney cancer （2.33/100 000） and testicular cancer （0.17/100 000）. The ranks of incidence and mortality of male urogenital tumors in China in 1990 were the same as those in 2019. In 2019， prostate cancer cases began to appear in the 20-year-old age group， bladder cancer cases in the 15-year-old age group， while kidney cancer and testicular cancer cases began to emerge in the 1-4-year-old age group. Before the age of 55， the incidence and mortality rates of four types of tumors in the male urogenital system did not differ significantly. After the age of 55， the incidence and mortality rate of prostate cancer surpassed those of kidney cancer， bladder cancer and testicular cancer. The incidence rate of male urogenital tumors in 2019 was higher in all age groups than in 1990. From 1990 to 2019， the incidence， mortality and standardized incidence rates of prostate cancer， bladder cancer， kidney cancer and testicular cancer all showed increasing trends. The standardized mortality rate of kidney cancer showed an upward trend， while prostate cancer exhibited a downward trend. Compared with global averages， the standardized incidence and mortality rates of male urogenital system tumors in China were lower in 1990 and 2019. Compared with different SDI regions， the standardized incidence and mortality rates of male kidney cancer， testicular cancer and bladder cancer in China in 1990 and 2019 were similar to those in moderate and low SDI regions. The standardized incidence and mortality rates of prostate cancer in 1990 and 2019 were lower in China than in different SDI regions. Conclusion In 1990 and 2019， the incidence and mortality ranks of male urogenital tumors in China are the same， with prostate cancer， bladder cancer， kidney cancer and testicular cancer in order from high to low. From 1990 to 2019， the incidence， mortality and standardized incidence rates of male urogenital system tumors in China show increasing trends. In 1990 and 2019， compared with the global average， the standardized incidence and mortality rates of male urogenital system tumors in China are lower.

Key words: Urogenital neoplasms, Kidney neoplasms, Urinary bladder neoplasms, Prostatic neoplasms, Testicular neoplasms, Incidence, Mortality

Zhao Mingjun, Yu Chunhu. Analysis of incidence and mortality of male urogenital system tumors in China from 1990 to 2019[J]. Journal of International Oncology, 2024, 51(10): 632-638.

Figures/Tables 6

References 14

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	Zi H, He SH, Leng XY, et al. Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990-2019[J]. Mil Med Res, 2021, 8(1): 60. DOI: 10.1186/s40779-021-00354-z. pmid: 34819142
[3]	Huang Q, Zi H, Luo L, et al. Secular trends of morbidity and mortality of prostate, bladder, and kidney cancers in China, 1990 to 2019 and their predictions to 2030[J]. BMC Cancer, 2022, 22(1): 1164. DOI: 10.1186/s12885-022-10244-9. pmid: 36368976
[4]	Xiang Z, Ye Z, Ma J, et al. Temporal trends and projections of bladder cancer burden in China from 1990 to 2030: findings from the Global Burden of Disease Study[J]. Clin Epidemiol, 2022, 14: 1305-1315. DOI: 10.2147/CLEP.S387289. pmid: 36387929
[5]	Lin L, Li Z, Yan L, et al. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019[J]. J Hematol Oncol, 2021, 14(1): 197. DOI: 10.1186/s13045-021-01213-z.
[6]	GBD 2019 Ageing Collaborators. Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study[J]. BMJ, 2022, 376: e068208. DOI: 10.1136/bmj-2021-068208.
[7]	Zhan Y, Pan C, Zhao Y, et al. Systematic analysis of the global, regional and national burden of kidney cancer from 1990 to 2017: results from the Global Burden of Disease Study 2017[J]. Eur Urol Focus, 2022, 8(1): 302-319. DOI: 10.1016/j.euf.2021.01.006.
[8]	Xie J, Wang M, Long Z, et al. Global burden of type 2 diabetes in adolescents and young adults, 1990-2019: systematic analysis of the Global Burden of Disease Study 2019[J]. BMJ, 2022, 379: e072385. DOI: 10.1136/bmj-2022-072385.
[9]	Murray CJL, Lopez AD. Measuring global health: motivation and evolution of the Global Burden of Disease Study[J]. Lancet, 2017, 390(10100): 1460-1464. DOI: 10.1016/S0140-6736(17)32367-X. pmid: 28919120
[10]	Akhtar S, Al-Abkal J, Alroughani R. Joinpoint regression analysis of trends in multiple sclerosis incidence in Kuwait: 1980-2019[J]. Neuroepidemiology, 2020, 54(6): 472-481. DOI: 10.1159/000511205. pmid: 33176327
[11]	Qin X, Ye D, Gu C, et al. Prostate cancer screening using prostate-specific antigen tests in a high-risk population in China: a cost-utility analysis[J]. Curr Ther Res Clin Exp, 2021, 95: 100653. DOI: 10.1016/j.curtheres.2021.100653.
[12]	Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis[J]. BMJ, 2018, 362: k3519. DOI: 10.1136/bmj.k3519.
[13]	Pinsky PF, Parnes H. Screening for prostate cancer[J]. N Engl J Med, 2023, 388(15): 1405-1414. DOI: 10.1056/NEJMcp2209151.
[14]	Johnstone SE, Gladyshev VN, Aryee MJ, et al. Epigenetic clocks, aging, and cancer[J]. Science, 2022, 378(6626): 1276-1277. DOI: 10.1126/science.abn4009. pmid: 36548410

癌种	发病例数	发病率（/10万）	死亡例数	死亡率（/10万）
前列腺癌
1990年	26 440	4.33	20 382	3.34
2019年	153 448	21.17	54 391	7.50
膀胱癌
1990年	18 362	3.01	11 910	1.95
2019年	82 681	11.41	31 505	4.35
肾癌
1990年	6 157	1.01	3 329	0.55
2019年	42 554	5.87	16 883	2.33
睾丸癌
1990年	3 233	0.53	782	0.13
2019年	17 169	2.37	1 205	0.17

年份	发病率				标化发病率
年份	肾癌	膀胱癌	前列腺癌	睾丸癌	肾癌	膀胱癌	前列腺癌	睾丸癌
1990	1.01	3.01	4.33	0.53	1.32	5.46	8.88	0.56
1991	1.04	3.10	4.53	0.56	1.36	5.52	9.06	0.58
1992	1.05	3.18	4.65	0.57	1.36	5.55	9.10	0.60
1993	1.06	3.26	4.84	0.58	1.36	5.59	9.26	0.62
1994	1.04	3.34	5.00	0.61	1.34	5.61	9.38	0.65
1995	1.06	3.43	5.22	0.63	1.35	5.64	9.52	0.69
1996	1.12	3.59	5.53	0.67	1.41	5.74	9.82	0.74
1997	1.18	3.76	5.82	0.70	1.47	5.83	10.01	0.77
1998	1.26	3.94	6.11	0.72	1.54	5.95	10.17	0.79
1999	1.38	4.11	6.44	0.75	1.65	6.03	10.39	0.83
2000	1.56	4.41	6.83	0.78	1.83	6.25	10.63	0.87
2001	1.79	4.63	7.24	0.80	2.06	6.36	10.92	0.89
2002	2.04	4.88	7.65	0.83	2.30	6.48	11.13	0.92
2003	2.36	5.24	8.18	0.90	2.58	6.69	11.44	0.98
2004	2.73	5.67	8.81	0.99	2.91	7.00	11.90	1.07
2005	3.00	5.94	9.35	1.04	3.12	7.15	12.27	1.12
2006	3.20	6.12	9.83	1.09	3.24	7.15	12.49	1.17
2007	3.43	6.48	10.52	1.18	3.39	7.35	12.91	1.26
2008	3.70	6.88	11.31	1.28	3.58	7.60	13.42	1.36
2009	4.00	7.37	12.20	1.39	3.80	7.92	13.98	1.48
2010	4.33	7.89	13.13	1.51	4.03	8.27	14.59	1.60
2011	4.53	8.23	13.82	1.57	4.14	8.41	14.90	1.67
2012	4.69	8.56	14.52	1.63	4.20	8.53	15.18	1.72
2013	4.78	8.82	15.16	1.72	4.20	8.58	15.37	1.80
2014	4.91	9.23	16.20	1.85	4.23	8.75	15.86	1.92
2015	4.95	9.56	16.93	1.93	4.20	8.85	16.09	1.98
2016	5.01	9.85	17.57	1.99	4.17	8.89	16.14	2.03
2017	5.26	10.33	18.73	2.14	4.31	9.06	16.57	2.17
2018	5.58	10.84	19.89	2.28	4.48	9.21	16.94	2.31
2019	5.87	11.41	21.17	2.37	4.63	9.38	17.34	2.39
AAPC（%）	6.23	4.63	5.92	5.32	4.45	1.92	2.32	5.12
95%CI（%）	5.91~6.52	4.21~5.13	5.72~6.01	5.12~5.68	4.01~4.78	1.63~2.14	2.13~2.56	4.72~5.59
P值	<0.05	<0.05	<0.05	<0.05	<0.05	<0.05	<0.05	<0.05

年份	死亡率				标化死亡率
年份	肾癌	膀胱癌	前列腺癌	睾丸癌	肾癌	膀胱癌	前列腺癌	睾丸癌
1990	0.55	1.95	3.34	0.13	0.85	4.43	8.22	0.16
1991	0.56	1.98	3.43	0.13	0.86	4.43	8.27	0.16
1992	0.56	2.02	3.50	0.13	0.85	4.41	8.22	0.16
1993	0.57	2.05	3.58	0.13	0.85	4.38	8.25	0.15
1994	0.56	2.09	3.67	0.13	0.84	4.38	8.31	0.16
1995	0.58	2.13	3.77	0.14	0.85	4.34	8.31	0.16
1996	0.60	2.18	3.90	0.14	0.87	4.34	8.39	0.16
1997	0.63	2.24	3.99	0.14	0.89	4.31	8.34	0.16
1998	0.66	2.31	4.08	0.14	0.93	4.31	8.27	0.16
1999	0.72	2.37	4.20	0.14	0.98	4.31	8.27	0.16
2000	0.80	2.50	4.34	0.14	1.07	4.36	8.25	0.16
2001	0.90	2.57	4.48	0.14	1.18	4.34	8.27	0.16
2002	1.02	2.64	4.57	0.14	1.29	4.30	8.16	0.15
2003	1.15	2.74	4.68	0.14	1.41	4.28	8.05	0.15
2004	1.30	2.87	4.83	0.14	1.55	4.33	8.04	0.15
2005	1.40	2.93	4.96	0.13	1.64	4.32	8.04	0.15
2006	1.46	2.93	5.02	0.13	1.67	4.20	7.92	0.14
2007	1.53	3.00	5.14	0.13	1.70	4.18	7.87	0.14
2008	1.62	3.09	5.30	0.13	1.76	4.20	7.88	0.13
2009	1.71	3.22	5.49	0.13	1.83	4.26	7.92	0.14
2010	1.83	3.35	5.69	0.13	1.92	4.33	7.99	0.14
2011	1.90	3.44	5.85	0.13	1.95	4.34	8.00	0.14
2012	1.95	3.53	6.01	0.14	1.96	4.35	8.02	0.14
2013	1.97	3.59	6.14	0.14	1.94	4.32	7.97	0.14
2014	2.00	3.70	6.37	0.14	1.92	4.33	8.00	0.14
2015	2.01	3.82	6.57	0.15	1.89	4.36	8.01	0.15
2016	2.04	3.94	6.78	0.15	1.87	4.36	7.96	0.15
2017	2.11	4.05	6.98	0.16	1.88	4.33	7.89	0.15
2018	2.21	4.17	7.19	0.16	1.91	4.28	7.77	0.15
2019	2.33	4.35	7.50	0.17	1.96	4.30	7.79	0.16
AAPC（%）	5.12	2.83	2.86	0.92	2.93	-0.12	-0.26	-0.14
95%CI（%）	4.82~5.35	2.51~3.02	2.61~3.02	0.61~1.22	2.61~3.32	-0.32~0.13	-0.36~-0.14	-0.31~0.24
P值	<0.05	<0.05	<0.05	<0.05	<0.05	>0.05	<0.05	>0.05

国家及地区	1990年标化发病率				2019年标化发病率
国家及地区	肾癌	膀胱癌	前列腺癌	睾丸癌	肾癌	膀胱癌	前列腺癌	睾丸癌
中国	1.32	5.46	8.88	0.56	4.63	9.38	17.34	2.39
全球	4.51	10.94	34.13	1.94	6.24	11.28	38.63	2.79
高SDI地区	10.02	18.07	75.24	6.76	12.54	18.62	79.70	7.75
中-高SDI地区	5.52	15.36	25.32	2.49	8.41	16.47	35.73	5.31
中SDI地区	1.47	4.67	14.48	0.65	3.50	7.31	23.64	1.99
中-低SDI地区	0.98	3.31	12.39	0.46	1.98	4.10	18.53	0.88
低SDI地区	1.03	4.72	16.25	0.41	1.50	4.77	20.25	0.59

国家及地区	1990年标化死亡率				2019年标化死亡率
国家及地区	肾癌	膀胱癌	前列腺癌	睾丸癌	肾癌	膀胱癌	前列腺癌	睾丸癌
中国	0.85	4.43	8.22	0.16	1.96	4.30	7.79	0.16
全球	2.50	6.13	18.13	0.31	2.98	5.09	15.27	0.28
高 SDI 地区	4.59	8.02	25.72	0.38	4.77	6.20	17.65	0.23
中-高 SDI地区	3.21	8.33	16.42	0.43	3.98	6.75	14.77	0.35
中 SDI地区	1.01	3.53	12.57	0.23	1.82	3.55	12.80	0.28
中-低 SDI地区	0.76	2.95	12.28	0.24	1.29	2.88	13.49	0.25
低 SDI地区	0.87	4.46	17.41	0.22	1.15	3.99	19.47	0.22